TABLE I.
Patient, tumour, and treatment characteristics
| Characteristic |
Patient group
|
p Valuea | ||
|---|---|---|---|---|
| Overall | Primary g-csf prophylaxis | |||
| Yes | No | |||
| Patients (n) | 239 | 145 | 94 | |
| Age (years) | ||||
| Median | 55 | 55 | 55 | 0.67 |
| Range | 32–80 | 32–75 | 33–80 | |
| Age ≥65 years [n (%)] | 42 (18) | 26 (18) | 16 (17) | 0.86 |
| Menopausal status [n (%)] | ||||
| Postmenopausal | 148 (62) | 96 (66) | 52 (55) | 0.09 |
| Pathology subtype [n (%)] | ||||
| Ductal | 211 (88) | 130 (90) | 81 (86) | 0.72 |
| Grade iii | 135 (56) | 90 (62) | 45 (48) | 0.10 |
| Receptor status [n (%)] | ||||
| er- or pr-positive | 164 (69) | 106 (73) | 58 (62) | 0.064 |
| her2-positive | 52 (22) | 26 (18) | 26 (28) | 0.06 |
| Triple negative | 52 (22) | 35 (24) | 17 (18) | 0.27 |
| Stage [n (%)] | ||||
| i | 53 (22) | 28 (19) | 25 (27) | 0.11 |
| ii | 127 (53) | 81 (56) | 46 (49) | |
| iii | 53 (22) | 30 (21) | 23 (24) | |
| Unknown | 6 (3) | 6 (4) | 0 (0) | |
| Type of surgery [n (%)] | ||||
| Breast-conservingb | 162 (68) | 100 (69) | 62 (66) | 0.63 |
| Mastectomyc | 77 (32) | 45 (31) | 32 (34) | |
| Chemotherapy agents [n (%)] | ||||
| Anthracycline-taxane regimensd | 212 (89) | 125 (86) | 87 (93) | 0.130 |
| Taxane only regimense | 27 (11) | 20 (14) | 7 (7) | |
| Trastuzumab-based therapy [n (%)] | 51 (21) | 25 (17) | 26 (28) | 0.055 |
a
Based on the Pearson or Fisher exact chi-square test and the t-test (Age).
b
Partial mastectomy, lumpectomy, or excisional biopsy with or without lymph node dissection.
c
Simple and modified radical mastectomy.
d
fec/d (5-fluorouracil–epirubicin–cyclophosphamide followed by docetaxel), n = 211; ac-t (doxorubicin–cyclophosphamide–paclitaxel), n = 1.
e
tc (docetaxel–cyclophosphamide), n = 26; tch (docetaxel–platinum and trastuzumab), n = 1. g-csf = granulocyte colony–stimulating factor; er = estrogen receptor; pr = progesterone receptor; her2 = human epidermal growth factor receptor 2.